Lucrative Business of Artemisinin from Artemisia Annua Plant. Producing Malaria Treatment at Large Scales.

Categories

Introduction:

Artemisinin: Artemisia (Artemisia annua), often known as sweet Annie or annual wormwood, is a Chinese annual plant known as qinghao. Artemisinin has been discovered to have quick and powerful antimalarial activity, even against drug-resistant forms of the parasite.

Related Project:- Production Of Artemisinin From Artemisia Annua Plant

It swiftly decreases fever and lowers parasite levels in the blood without causing severe negative effects. Artemisinin-combination therapies (ACTs) containing an artemisinin derivative are now the standard treatment for P. falciparum malaria around the world. Malaria and parasitic worm (helminth) infections have been treated with artemisinin and its derivatives. They have an advantage over other medications in that they can kill parasites faster and at all phases of their life cycle. However, inadequate bioavailability, poor pharmacokinetic characteristics, and expensive drug costs are key negatives.

Start a Business in India, Click Here

Start a Business in Middle East, Click Here

About Artemisia Annua Plant:

Sweet wormwood, sweet Annie, and qinghao are all common names for Artemisia annua, a shrub native to China that has long been utilised for both ornamental and medicinal uses. A. annua is now grown all over the world as the only source of artemisinin, a powerful anti-malarial medicine.

Related Videos:- Herbs and Herbal Based Products

The drug is part of a cocktail of phytochemicals stored in glands on the epidermis of the leaves, known as “glandular trichomes,” and utilised to keep browsers away. Artemisinin has proven to be effective against the highly adaptable malaria parasite, which has already developed resistance to a number of other medications.

Start a Business in Africa, Click Here

Start a Business in Asia, Click Here

Uses:

The World Health Organization (WHO) recommends artemisinin or one of its derivatives as first-line treatment for all cases of malaria, usually in combination with a longer-acting companion medicine. The WHO advises three days of oral treatment with one of five artemisinin-based combination treatments (ACTs) for uncomplicated malaria.

The artemisinin derivative kills the parasites quickly in each of these combinations, but it is quickly removed from the body. The longer-acting companion medicine eliminates any remaining parasites while also providing some protection against reinfection.

Start a Business in Potential Countries for Doing Business, Click Here

Best Industry for Doing Business, Click Here

Market Outlook:

Plasmodium falciparum malaria is treated with artemisinin combination therapy (ACT). Due to the significant prevalence of malaria, especially in emerging and underdeveloped nations, this market has been growing in recent years. Because of its expanding application scope in the pharmaceutical industry, the worldwide artemisinin market is predicted to increase significantly over the period.

Related Projects: – Herbs and Herbal Based Products

WHO recognition of artemisinin-based combination therapy (ACT) as a first-line treatment for malaria, demand for artemisinin has increased significantly over the last decade. Because of the huge production base of artemisinin herbs and the growing need for artemisinin-based therapy in malaria-endemic areas, Asia Pacific and Africa held the greatest market share for artemisinin and its derivatives.

Market Research: Market Research Report

The largest consumer regions are Europe and India. In 2015, Europe’s consumption was estimated to be around 107 MT. India’s consumption has fluctuated in recent years, accounting for roughly 26% of total in 2015.

For More Details: Click Here

Major Players: